Sector News

Amryt buys Aegerion via bankruptcy, adding sales to support R&D

September 25, 2019
Life sciences

Amryt Pharma has completed the acquisition of Aegerion Pharmaceuticals. The deal, which comes after Aegerion filed for Chapter 11 bankruptcy, gives Amryt near-full control of two commercial drugs that could provide revenues to support its protracted attempt to get AP101 to market.

Aegerion won FDA approval for cholesterol drug Juxtapid late in 2012 and completed a $325 million convertible debt offering two years later. Shortly after the debt offering, Aegerion paid AstraZeneca $325 million for leptin deficiency drug Myalept. The actions gave Aegerion two commercial drugs, but neither proved to be a big enough success to support the debt it took on.

Amryt picked up the European rights to Juxtapid from Aegerion late in 2016 in a deal that lacked an upfront component. And earlier this year, it put together an all-stock deal designed to free Aegerion from debt and transfer ownership of the business to Amryt.

The completion of that deal leaves Amryt with the near-global rights to Juxtapid and Myalept. Last year, the products generated sales of $136.5 million. Amryt will look to grow that figure, although it faces patent expirations in the coming years that may limit the longer-term prospects of the drugs.

By then, Amryt may have brought its lead candidate, epidermolysis bullosa treatment AP101, to market. A pivotal trial of the drug has taken longer than expected, with Amryt pushing back the targeted readout by about a year to buy it time to enroll more patients than initially expected.

Amryt expects to deliver data next year, and, under the terms of its deal with Aegerion, will pay out if the drug comes to market in the U.S. or Europe before July 2022. The Aegerion deal also features a payment tied to the sales AP101 generates before the start of July 2024.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

March 2, 2024

Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024

Life sciences

After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.

March 2, 2024

Argenx goes again, ramping up unbranded campaign ahead of hoped-for label expansion

Life sciences

Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.

March 2, 2024

EuroAPI appoints new CEO and lays out restructuring plan as manufacturer’s losses mount

Life sciences

Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.

How can we help you?

We're easy to reach